PMV Pharma Launches Public Offering of Stock and Warrants Amid Cash Crunch
PMVP is trading near its 52-week low of $1.02 (0.0% above the low).
Summary
PMV Pharma announced an underwritten public offering of common stock and warrants, with pre-funded warrants for certain investors. The offering size and terms are not yet disclosed, but the company's recent 10-Q revealed a going concern warning with cash runway under one year and only $79.4 million in cash as of June 30, 2026. This capital raise is critical for funding operations and the upcoming NDA submission for rezatapopt. The stock is trading near its 52-week low at $1.02, making the offering highly dilutive at current prices. Investors will watch for the final pricing and size of the offering, which will determine the extent of dilution and whether the company can extend its runway.
At the time of this announcement, PMVP was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.7M. The 52-week trading range was $1.02 to $1.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.